Patents Assigned to FENNEC PHARMACEUTICALS, INC.
  • Anhydrous Sodium Thiosulfate and Formulations Thereof
    Publication number: 20240350637
    Abstract: Described herein is anhydrous sodium thiosulfate, methods for synthesizing anhydrous sodium thiosulfate, pharmaceutical compositions thereof, and methods of treating ototoxicity. Anhydrous sodium thiosulfate is synthesized from sodium sulfite, sulfur, and cetylpyridinium chloride. The anhydrous sodium thiosulfate is formulated into a pharmaceutical composition comprising a buffer and solvent. These compositions are useful for eliminating or reducing ototoxicity in pediatric patients receiving platinum-based chemotherapeutics.
    Type: Application
    Filed: November 6, 2023
    Publication date: October 24, 2024
    Applicant: Fennec Pharmaceuticals Inc.
    Inventors: Thomas Claiborne Lovelace, Joseph Alexander Moore, III, Christopher McKinnon Lee, Daniel Logan Kirschner
  • THERAPEUTIC USES FOR SODIUM THIOSULFATE FORMULATIONS
    Publication number: 20240216511
    Abstract: Described herein is anhydrous sodium thiosulfate, methods for synthesizing anhydrous sodium thiosulfate, pharmaceutical compositions thereof, and methods of treating ototoxicity. Anhydrous sodium thiosulfate is synthesized from sodium sulfite, sulfur, and cetylpyridinium chloride. The anhydrous sodium thiosulfate is formulated into a pharmaceutical composition comprising a buffer and solvent. These compositions are useful for eliminating or reducing ototoxicity in pediatric patients receiving platinum-based chemotherapeutics.
    Type: Application
    Filed: March 15, 2024
    Publication date: July 4, 2024
    Applicant: Fennec Pharmaceuticals, Inc.
    Inventor: Alexander Smith
  • Therapeutic uses for sodium thiosulfate formulations
    Patent number: 11998604
    Abstract: Described herein is anhydrous sodium thiosulfate, methods for synthesizing anhydrous sodium thiosulfate, pharmaceutical compositions thereof, and methods of treating ototoxicity. Anhydrous sodium thiosulfate is synthesized from sodium sulfite, sulfur, and cetylpyridinium chloride. The anhydrous sodium thiosulfate is formulated into a pharmaceutical composition comprising a buffer and solvent. These compositions are useful for eliminating or reducing ototoxicity in pediatric patients receiving platinum-based chemotherapeutics.
    Type: Grant
    Filed: November 22, 2022
    Date of Patent: June 4, 2024
    Assignee: Fennec Pharmaceuticals Inc.
    Inventor: Alexander Smith
  • Anhydrous Sodium Thiosulfate and Formulations Thereof
    Publication number: 20240165237
    Abstract: Described herein is anhydrous sodium thiosulfate, methods for synthesizing anhydrous sodium thiosulfate, pharmaceutical compositions thereof, and methods of treating ototoxicity. Anhydrous sodium thiosulfate is synthesized from sodium sulfite, sulfur, and cetylpyridinium chloride. The anhydrous sodium thiosulfate is formulated into a pharmaceutical composition comprising a buffer and solvent. These compositions are useful for eliminating or reducing ototoxicity in pediatric patients receiving platinum-based chemotherapeutics.
    Type: Application
    Filed: November 6, 2023
    Publication date: May 23, 2024
    Applicant: Fennec Pharmaceuticals Inc.
    Inventors: Thomas Claiborne Lovelace, Joseph Alexander Moore, III, Christopher McKinnon Lee, Daniel Logan Kirschner
  • Therapeutic uses for sodium thiosulfate formulations
    Patent number: 11964018
    Abstract: Described herein is anhydrous sodium thiosulfate, methods for synthesizing anhydrous sodium thiosulfate, pharmaceutical compositions thereof, and methods of treating ototoxicity. Anhydrous sodium thiosulfate is synthesized from sodium sulfite, sulfur, and cetylpyridinium chloride. The anhydrous sodium thiosulfate is formulated into a pharmaceutical composition comprising a buffer and solvent. These compositions are useful for eliminating or reducing ototoxicity in pediatric patients receiving platinum-based chemotherapeutics.
    Type: Grant
    Filed: November 22, 2022
    Date of Patent: April 23, 2024
    Assignee: Fennec Pharmaceuticals Inc.
    Inventor: Alexander Smith
  • ANHYDROUS SODIUM THIOSULFATE AND FORMULATIONS THEREOF
    Publication number: 20240042036
    Abstract: Described herein is anhydrous sodium thiosulfate, methods for synthesizing anhydrous sodium thiosulfate, pharmaceutical compositions thereof, and methods of treating ototoxicity. Anhydrous sodium thiosulfate is synthesized from sodium sulfite, sulfur, and cetylpyridinium chloride. The anhydrous sodium thiosulfate is formulated into a pharmaceutical composition comprising a buffer and solvent. These compositions are useful for eliminating or reducing ototoxicity in pediatric patients receiving platinum-based chemotherapeutics.
    Type: Application
    Filed: September 29, 2023
    Publication date: February 8, 2024
    Applicant: Fennec Pharmaceuticals Inc
    Inventors: Thomas Claiborne Lovelace, Joseph Alexander Moore, III, Christopher McKinnon Lee, Daniel Logan Kirschner
  • ANHYDROUS SODIUM THIOSULFATE AND FORMULATIONS THEREOF
    Publication number: 20230201351
    Abstract: Described herein is anhydrous sodium thiosulfate, methods for synthesizing anhydrous sodium thiosulfate, pharmaceutical compositions thereof, and methods of treating ototoxicity. Anhydrous sodium thiosulfate is synthesized from sodium sulfite, sulfur, and cetylpyridinium chloride. The anhydrous sodium thiosulfate is formulated into a pharmaceutical composition comprising a buffer and solvent. These compositions are useful for eliminating or reducing ototoxicity in pediatric patients receiving platinum-based chemotherapeutics.
    Type: Application
    Filed: February 20, 2023
    Publication date: June 29, 2023
    Applicant: Fennec Pharmaceuticals Inc.
    Inventors: Thomas Claiborne Lovelace, Joseph Alexander Moore, III, Christopher McKinnon Lee, Daniel Logan Kirschner
  • ANHYDROUS SODIUM THIOSULFATE AND FORMULATIONS THEREOF
    Publication number: 20230201350
    Abstract: Described herein is anhydrous sodium thiosulfate, methods for synthesizing anhydrous sodium thiosulfate, pharmaceutical compositions thereof, and methods of treating ototoxicity. Anhydrous sodium thiosulfate is synthesized from sodium sulfite, sulfur, and cetylpyridinium chloride. The anhydrous sodium thiosulfate is formulated into a pharmaceutical composition comprising a buffer and solvent. These compositions are useful for eliminating or reducing ototoxicity in pediatric patients receiving platinum-based chemotherapeutics.
    Type: Application
    Filed: February 20, 2023
    Publication date: June 29, 2023
    Applicant: Fennec Pharmaceuticals Inc.
    Inventors: Thomas Claiborne Lovelace, Joseph Alexander Moore, III, Christopher McKinnon Lee, Daniel Logan Kirschner
  • ANHYDROUS SODIUM THIOSULFATE AND FORMULATIONS THEREOF
    Publication number: 20230201349
    Abstract: Described herein is anhydrous sodium thiosulfate, methods for synthesizing anhydrous sodium thiosulfate, pharmaceutical compositions thereof, and methods of treating ototoxicity. Anhydrous sodium thiosulfate is synthesized from sodium sulfite, sulfur, and cetylpyridinium chloride. The anhydrous sodium thiosulfate is formulated into a pharmaceutical composition comprising a buffer and solvent. These compositions are useful for eliminating or reducing ototoxicity in pediatric patients receiving platinum-based chemotherapeutics.
    Type: Application
    Filed: February 20, 2023
    Publication date: June 29, 2023
    Applicant: Fennec Pharmaceuticals Inc.
    Inventors: Thomas Claiborne Lovelace, Joseph Alexander Moore, III, Christopher McKinnon Lee, Daniel Logan Kirschner
  • ANHYDROUS SODIUM THIOSULFATE AND FORMULATIONS THEREOF
    Publication number: 20230158145
    Abstract: Described herein is anhydrous sodium thiosulfate, methods for synthesizing anhydrous sodium thiosulfate, pharmaceutical compositions thereof, and methods of treating ototoxicity. Anhydrous sodium thiosulfate is synthesized from sodium sulfite, sulfur, and cetylpyridinium chloride. The anhydrous sodium thiosulfate is formulated into a pharmaceutical composition comprising a buffer and solvent. These compositions are useful for eliminating or reducing ototoxicity in pediatric patients receiving platinum-based chemotherapeutics.
    Type: Application
    Filed: November 22, 2022
    Publication date: May 25, 2023
    Applicant: Fennec Pharmaceuticals Inc.
    Inventors: Thomas Claiborne Lovelace, Joseph Alexander Moore, III, Christopher McKinnon Lee, Daniel Logan Kirschner
  • Anhydrous sodium thiosulfate and formulations thereof
    Patent number: 11617793
    Abstract: Described herein is anhydrous sodium thiosulfate, methods for synthesizing anhydrous sodium thiosulfate, pharmaceutical compositions thereof, and methods of treating ototoxicity. Anhydrous sodium thiosulfate is synthesized from sodium sulfite, sulfur, and cetylpyridinium chloride. The anhydrous sodium thiosulfate is formulated into a pharmaceutical composition comprising a buffer and solvent. These compositions are useful for eliminating or reducing ototoxicity in pediatric patients receiving platinum-based chemotherapeutics.
    Type: Grant
    Filed: July 22, 2022
    Date of Patent: April 4, 2023
    Assignee: Fennec Pharmaceuticals, Inc.
    Inventors: Thomas Claiborne Lovelace, Joseph Alexander Moore, III, Christopher Mckinnon Lee, Daniel Logan Kirschner
  • ANHYDROUS SODIUM THIOSULFATE AND FORMULATIONS THEREOF
    Publication number: 20230094886
    Abstract: Described herein is anhydrous sodium thiosulfate, methods for synthesizing anhydrous sodium thiosulfate, pharmaceutical compositions thereof, and methods of treating ototoxicity. Anhydrous sodium thiosulfate is synthesized from sodium sulfite, sulfur, and cetylpyridinium chloride. The anhydrous sodium thiosulfate is formulated into a pharmaceutical composition comprising a buffer and solvent. These compositions are useful for eliminating or reducing ototoxicity in pediatric patients receiving platinum-based chemotherapeutics.
    Type: Application
    Filed: November 22, 2022
    Publication date: March 30, 2023
    Applicant: Fennec Pharmaceuticals Inc.
    Inventors: Thomas Claiborne Lovelace, Joseph Alexander Moore, III, Chirstopher McKinnon Lee, Daniel Logan Kirschner
  • ANHYDROUS SODIUM THIOSULFATE AND FORMULATIONS THEREOF
    Publication number: 20230094842
    Abstract: Described herein is anhydrous sodium thiosulfate, methods for synthesizing anhydrous sodium thiosulfate, pharmaceutical compositions thereof, and methods of treating ototoxicity. Anhydrous sodium thiosulfate is synthesized from sodium sulfite, sulfur, and cetylpyridinium chloride. The anhydrous sodium thiosulfate is formulated into a pharmaceutical composition comprising a buffer and solvent. These compositions are useful for eliminating or reducing ototoxicity in pediatric patients receiving platinum-based chemotherapeutics.
    Type: Application
    Filed: November 22, 2022
    Publication date: March 30, 2023
    Applicant: Fennec Pharmaceuticals Inc.
    Inventors: Thomas Claiborne Lovelace, Joseph Alexander Moore, III, Christopher McKinnon Lee, Daniel Logan Kirschner
  • ANHYDROUS SODIUM THIOSULFATE AND FORMULATIONS THEREOF
    Publication number: 20220378915
    Abstract: Described herein is anhydrous sodium thiosulfate, methods for synthesizing anhydrous sodium thiosulfate, pharmaceutical compositions thereof, and methods of treating ototoxicity. Anhydrous sodium thiosulfate is synthesized from sodium sulfite, sulfur, and cetylpyridinium chloride. The anhydrous sodium thiosulfate is formulated into a pharmaceutical composition comprising a buffer and solvent. These compositions are useful for eliminating or reducing ototoxicity in pediatric patients receiving platinum-based chemotherapeutics.
    Type: Application
    Filed: July 22, 2022
    Publication date: December 1, 2022
    Applicant: Fennec Pharmaceuticals Inc.
    Inventors: Thomas Claiborne Lovelace, Joseph Alexander Moore, III, Christopher McKinnon Lee, Daniel Logan Kirschner
  • Anhydrous sodium thiosulfate and formulations thereof
    Patent number: 11510984
    Abstract: Described herein is anhydrous sodium thiosulfate, methods for synthesizing anhydrous sodium thiosulfate, pharmaceutical compositions thereof, and methods of treating ototoxicity. Anhydrous sodium thiosulfate is synthesized from sodium sulfite, sulfur, and cetylpyridinium chloride. The anhydrous sodium thiosulfate is formulated into a pharmaceutical composition comprising a buffer and solvent. These compositions are useful for eliminating or reducing ototoxicity in pediatric patients receiving platinum-based chemotherapeutics.
    Type: Grant
    Filed: June 24, 2022
    Date of Patent: November 29, 2022
    Assignee: Fennec Pharmaceuticals, Inc.
    Inventors: Thomas Claiborne Lovelace, Joseph Alexander Moore, III, Christopher McKinnon Lee, Daniel Logan Kirschner
  • ANHYDROUS SODIUM THIOSULFATE AND FORMULATIONS THEREOF
    Publication number: 20220323586
    Abstract: Described herein is anhydrous sodium thiosulfate, methods for synthesizing anhydrous sodium thiosulfate, pharmaceutical compositions thereof, and methods of treating ototoxicity. Anhydrous sodium thiosulfate is synthesized from sodium sulfite, sulfur, and cetylpyridinium chloride. The anhydrous sodium thiosulfate is formulated into a pharmaceutical composition comprising a buffer and solvent. These compositions are useful for eliminating or reducing ototoxicity in pediatric patients receiving platinum-based chemotherapeutics.
    Type: Application
    Filed: June 24, 2022
    Publication date: October 13, 2022
    Applicant: Fennec Pharmaceuticals Inc.
    Inventors: Thomas Claiborne Lovelace, Joseph Alexander Moore, III, Christopher McKinnon Lee, Daniel Logan Kirschner
  • ANHYDROUS SODIUM THIOSULFATE AND FORMULATIONS THEREOF
    Publication number: 20220160875
    Abstract: Described herein is anhydrous sodium thiosulfate, methods for synthesizing anhydrous sodium thiosulfate, pharmaceutical compositions thereof, and methods of treating ototoxicity. Anhydrous sodium thiosulfate is synthesized from sodium sulfite, sulfur, and cetylpyridinium chloride. The anhydrous sodium thiosulfate is formulated into a pharmaceutical composition comprising a buffer and solvent. These compositions are useful for eliminating or reducing ototoxicity in pediatric patients receiving platinum-based chemotherapeutics.
    Type: Application
    Filed: January 25, 2022
    Publication date: May 26, 2022
    Applicant: Fennec Pharmaceuticals Inc.
    Inventors: Thomas Claiborne Lovelace, Joseph Alexander Moore, III, Christopher McKinnon Lee, Daniel Logan Kirschner
  • Anhydrous sodium thiosulfate and formulations thereof
    Patent number: 11291728
    Abstract: Described herein is anhydrous sodium thiosulfate, methods for synthesizing anhydrous sodium thiosulfate, pharmaceutical compositions thereof, and methods of treating ototoxicity. Anhydrous sodium thiosulfate is synthesized from sodium sulfite, sulfur, and cetylpyridinium chloride. The anhydrous sodium thiosulfate is formulated into a pharmaceutical composition comprising a buffer and solvent. These compositions are useful for eliminating or reducing ototoxicity in pediatric patients receiving platinum based chemotherapeutics.
    Type: Grant
    Filed: August 28, 2020
    Date of Patent: April 5, 2022
    Assignee: FENNEC PHARMACEUTICALS, INC.
    Inventors: Thomas Claiborne Lovelace, Joseph Alexander Moore, III, Christopher McKinnon Lee, Daniel Logan Kirschner
  • Anhydrous sodium thiosulfate and formulations thereof
    Patent number: 10792363
    Abstract: Described herein is anhydrous sodium thiosulfate, methods for synthesizing anhydrous sodium thiosulfate, pharmaceutical compositions thereof, and methods of treating ototoxicity. Anhydrous sodium thiosulfate is synthesized from sodium sulfite, sulfur, and cetylpyridinium chloride. The anhydrous sodium thiosulfate is formulated into a pharmaceutical composition comprising a buffer and solvent. These compositions are useful for eliminating or reducing ototoxicity in pediatric patients receiving platinum based chemotherapeutics.
    Type: Grant
    Filed: July 1, 2019
    Date of Patent: October 6, 2020
    Assignee: FENNEC PHARMACEUTICALS, INC.
    Inventors: Thomas Claiborne Lovelace, Joseph Alexander Moore, III, Christopher McKinnon Lee, Daniel Logan Kirschner